Venus Remedies Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Venus Remedies has been growing earnings at an average annual rate of 17.2%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 8.3% per year. Venus Remedies's return on equity is 4.5%, and it has net margins of 3.6%.
Belangrijke informatie
17.2%
Groei van de winst
16.4%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.5% |
| Inkomstengroei | 8.3% |
| Rendement op eigen vermogen | 4.5% |
| Nettomarge | 3.6% |
| Volgende winstupdate | 14 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Venus Remedies geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 6,146 | 221 | 1,739 | 169 |
| 30 Jun 24 | 6,149 | 285 | 1,734 | 165 |
| 31 Mar 24 | 6,014 | 285 | 1,697 | 158 |
| 31 Dec 23 | 5,619 | 290 | 1,596 | 158 |
| 30 Sep 23 | 5,354 | 255 | 1,527 | 190 |
| 30 Jun 23 | 5,076 | 209 | 1,384 | 203 |
| 31 Mar 23 | 5,555 | 266 | 1,397 | 229 |
| 31 Dec 22 | 5,418 | 157 | 1,353 | 261 |
| 30 Sep 22 | 5,492 | 181 | 1,352 | 249 |
| 30 Jun 22 | 6,119 | 359 | 1,332 | 267 |
| 31 Mar 22 | 6,002 | 407 | 1,281 | 230 |
| 31 Dec 21 | 5,702 | 756 | 1,225 | 193 |
| 30 Sep 21 | 5,684 | 816 | 1,214 | 182 |
| 30 Jun 21 | 5,087 | 715 | 1,243 | 149 |
| 31 Mar 21 | 5,481 | 618 | 1,378 | 158 |
| 31 Dec 20 | 5,320 | 213 | 1,471 | 159 |
| 30 Sep 20 | 4,939 | 87 | 1,431 | 158 |
| 30 Jun 20 | 4,586 | -40 | 1,338 | 144 |
| 31 Mar 20 | 3,407 | -100 | 1,100 | 143 |
| 31 Dec 19 | 3,490 | -161 | 1,026 | 147 |
| 30 Sep 19 | 3,281 | -269 | 995 | 145 |
| 30 Jun 19 | 3,286 | -269 | 960 | 149 |
| 31 Mar 19 | 3,219 | -286 | 928 | 147 |
| 31 Mar 18 | 3,724 | -307 | 972 | 306 |
| 31 Mar 17 | 4,000 | -171 | 409 | 278 |
| 31 Mar 16 | 4,183 | 17 | 437 | 0 |
| 31 Mar 15 | 4,640 | 52 | 496 | 0 |
| 31 Mar 14 | 5,416 | 643 | 775 | 167 |
Kwaliteitswinsten: 526953 has high quality earnings.
Groeiende winstmarge: 526953's current net profit margins (3.6%) are lower than last year (4.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 526953 has become profitable over the past 5 years, growing earnings by 17.2% per year.
Versnelling van de groei: 526953's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 526953 had negative earnings growth (-13.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.1%).
Rendement op eigen vermogen
Hoge ROE: 526953's Return on Equity (4.5%) is considered low.